Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 4

2(33.3%)

Phase 1

1(16.7%)

6Total

N/A(3)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05504954Not ApplicableCompleted

A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA

Role: collaborator

NCT03977181Not ApplicableCompleted

The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms

Role: collaborator

NCT04166474Phase 4Completed

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

Role: collaborator

NCT03892161Phase 1Terminated

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

Role: collaborator

NCT03142256Phase 4Unknown

3Ps for Prevention Study (Perception, Partners, Pills)

Role: lead

NCT02404038Not ApplicableUnknown

A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods

Role: lead

NCT02419066Completed

Examining HIV Treatment Adherence During Early Disease

Role: collaborator

NCT00944879Unknown

Preparing for Adolescent HIV Vaccine Trials in South Africa:

Role: lead

All 8 trials loaded